Costs and Utilization of End-stage Glaucoma Patients Receiving Visual Rehabilitation Care: A US Multisite Retrospective Study
| Autor: | Bruce P Rosenthal, Laura M. Katz, David K. Gieser, Lujing Wang, R. Tracy Williams, John G. Walt, Lisa C. Rosenblatt, Lee Stern, John Doyle, William O'Connell, Lisa R. Siegartel, Louis R. Pasquale |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male medicine.medical_specialty genetic structures Visual rehabilitation MEDLINE Vision Low Glaucoma Disease Blindness Cost of Illness Chart review medicine Humans Aged Retrospective Studies Aged 80 and over business.industry Health services research Retrospective cohort study Health Care Costs Middle Aged medicine.disease United States eye diseases Ophthalmology End-stage glaucoma Sensory Aids Physical therapy Health Resources Female Health Services Research business Glaucoma Open-Angle |
| Zdroj: | Journal of Glaucoma. 15:419-425 |
| ISSN: | 1057-0829 |
| DOI: | 10.1097/01.ijg.0000212250.95078.6f |
| Popis: | Glaucoma is a prevalent ophthalmologic disease and leading cause of blindness. A retrospective analysis was conducted to evaluate resources and costs for end-stage glaucoma patients receiving visual rehabilitation care (VRC).A chart review was conducted in 3 United States VRC centers. Charts of patients with primary open-angle glaucoma as the primary cause of vision loss (1998 to 2003) were selected, yielding 81 records. Data were collected from patient-level billing and reimbursement records (ophthalmologist/optometrist visits, glaucoma medications, procedures, and specialized low-vision and glaucoma-related services). Visual rehabilitation services included utilization of low-vision devices, assessment of daily functioning, orientation and mobility training, and patient counseling.Mean age at baseline was 72.7 years [standard deviation (SD)=17.2, range: 29 to 95]. Of those with known sex (n=77), 55.8% were women. Medicare was the payer type for most patients (59.3%), whereas 20% had Medicaid. Mean number of visits was 7.1 (SD=6.1) in year 1 and 3.7 (SD=4.2) in year 2, for an annual mean of 5.4 (SD=5.0) visits overall. Total mean cost per patient in year 1 was greater than year 2 [$2170 (SD=$2252) vs. $1202 (SD=$1080), respectively]; of the total 2-year costs, 15% were VRC, 37% ophthalmology care, and 48% pharmacy. Analysis of nonpharmacy costs revealed that VRC accounted for 28% and ophthalmology for 72%.End-stage glaucoma is associated with appreciable resource utilization and costs, because of both vision rehabilitation and ophthalmology care. Advanced primary open-angle glaucoma has a substantial cost-of-illness, warranting improved management in early stages of disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|